Severe Salicylate Poisoning Decision Pathway

1. Suspect significant salicylate toxicity: obtain serial salicylate concentrations, blood gas, electrolytes, renal function, glucose, and continuous clinical reassessment. Treat the patient, not a single number.

2. Correct volume depletion, potassium, magnesium, and glucose. Start IV sodium bicarbonate when symptomatic or acid-base toxicity is present, including patients who remain mildly alkalemic from respiratory alkalosis. [1]

3. Assess gastrointestinal decontamination by formulation, dose, time since ingestion, aspiration risk, and evidence of ongoing absorption. [3]

4. Escalate early if mental status worsens, hypoxemia develops, acidemia progresses, alkalinization fails, renal function is impaired, pulmonary edema limits bicarbonate, or the salicylate concentration meets EXTRIP criteria. [1,2]

5. If airway control becomes unavoidable, minimize apnea, use peri-intubation bicarbonate when indicated, and immediately match or exceed the patient’s pre-intubation minute ventilation. In severe poisoning, consider arranging dialysis before or at intubation when clinically feasible and indications are present or anticipated. [Observational / Expert; 1,5,6,8]

6. During ECTR, reassess cessation using clinical improvement plus the EXTRIP concentration or duration endpoint. Continue indicated bicarbonate between sessions. [2] After ECTR, recheck salicylate at 2–6 hours for rebound, sooner if deterioration occurs. [Expert]

Bedside Treatment Box

Exposure Context and Formulations

Formulation matters because delayed gastric emptying, pylorospasm, enteric coating, modified-release formulations, and tablet concretions can prolong absorption well beyond the expected therapeutic peak. A single early concentration after an enteric-coated or modified-release overdose is not reassuring.

Methyl Salicylate

Concentrated oil of wintergreen requires special caution. Approximately 1 mL of 98% methyl salicylate is equivalent to about 1.4 g of aspirin on a molar basis. Published out-of-hospital referral criteria call for emergency evaluation after more than a lick or taste in a child younger than 6 years, or more than 4 mL in a patient 6 years or older. [4]

MedicalToxic takes a deliberately more conservative editorial position for children: any reported ingestion of a concentrated methyl salicylate product should be treated as potentially lethal and referred because caregiver volume estimates are unreliable and the margin is small. [Expert]

Mechanism of Toxicity

• Uncoupling of oxidative phosphorylation and inhibition of Krebs-cycle enzymes increase heat production, oxygen consumption, lactate, and ketoacid generation.

• Direct stimulation of the medullary respiratory center produces early hyperpnea and respiratory alkalosis.

• Falling blood pH increases the non-ionized fraction of salicylic acid and accelerates CNS penetration. [12]

• Metabolic clearance becomes capacity-limited in overdose, while renal elimination remains strongly pH-dependent.

• CNS glucose utilization increases; neuroglycopenia may occur despite a normal serum glucose. [10,11]

• Volume depletion and whole-body potassium loss are common and directly impair urinary alkalinization. [1]

Dose and Risk Assessment

Estimated dose is useful for triage of an asymptomatic acute ingestion but becomes a poor predictor once symptoms or chronic exposure are present. The historical acute dose strata below should not override clinical assessment or serial concentrations. [1]

• The 150 mg/kg referral threshold is a screening tool, not a safety guarantee.

• Chronic or repeated exposure is not captured by acute dose strata.

• Concentrated methyl salicylate should be converted to aspirin-equivalent dose and handled separately.

• Intentional exposure, symptoms, concentrated methyl salicylate exposure, or unknown dose with a compatible acid-base pattern warrants evaluation regardless of a reassuring calculated dose. [Expert]

Focused History

• Exact product and salicylate formulation.

• Tablet strength or liquid concentration and maximum possible amount.

• Time of exposure and whether the pattern is acute, repeated/chronic, acute-on-chronic, delayed, or unknown.

• Intentional versus unintentional exposure.

• Co-ingestants and comorbidities, especially renal, pulmonary, or cardiovascular disease.

• Body weight when dose-based interpretation is needed.

• Symptoms, including tinnitus, altered hearing, vomiting, hyperpnea, dyspnea, confusion, seizure, hyperthermia, and reduced urine output.

• Treatments already given, including charcoal, bicarbonate, ventilation, or dialysis.

Evaluation and Monitoring

Testing below is a MedicalToxic operational assessment framework, informed by ACMT and individualized to presentation; not every test is mandatory in every low-risk exposure. [1] [Expert]

Unit Conversion and Laboratory Interference

Serum salicylate: mg/dL × 0.0724 ≈ mmol/L; mg/dL × 10 = mg/L. Confirm the unit on every result. The conversion table is arithmetic only, not a severity classification. [1,2]

100 mg/dL = 1,000 mg/L ≈ 7.24 mmol/L. A mg/L result must not be treated as mg/dL. Published EXTRIP cutoffs retain the rounded mmol/L equivalents used by that source. [1,2]

• Diflunisal can cross-react with some salicylate assays; a measured salicylate concentration may therefore be misleading when diflunisal is present. If the result conflicts with the clinical picture, contact the laboratory and confirm the assay method. [1]

• Interference is assay-specific: colorimetric methods, including Trinder-based assays, can be affected by endogenous or exogenous substances. Do not assume that all methods or interferents have the same effect. Ask the laboratory to identify the method and relevant interference limits. [13]

• Hemolysis and lipemia can affect some spectrophotometric salicylate assays; the direction and magnitude depend on the platform and specimen. Request laboratory assessment and a repeat or alternative-method measurement when appropriate. Do not dismiss suspected toxicity or delay clinically indicated treatment while investigating a discordant result. [14] [Expert]

Serial Salicylate Concentrations

• ACMT recommends frequent serial concentrations interpreted in clinical and acid-base context; it does not specify one universal sampling interval. [1]

• MedicalToxic operational schedule: repeat concentrations every 2 hours during evolving toxicity and every 1–2 hours if deteriorating; obtain an immediate reassessment for new instability rather than waiting for the next scheduled sample. These intervals are editorial protocol choices. A recent narrative review also describes two-hour sampling. [Expert; 9]

• Continue until concentrations are clearly and consistently declining. One falling value is not enough when delayed absorption is plausible.

• During active systemic toxicity, pair scheduled salicylate samples with a blood gas as a MedicalToxic operational approach. Interpret every result using the current acid-base assessment; the paired-sample schedule is not a separately graded ACMT recommendation. [Expert]

• Clinical deterioration despite a falling concentration is an ominous sign and should not be treated as biochemical improvement. [1]

Clinical Manifestations and Severity

Severity is staged by clinical findings and acid-base pattern, not by concentration. A patient meeting a severe clinical descriptor is severely poisoned at any concentration. EXTRIP ECTR criteria should be assessed independently of severity stage. [1,2]

Diagnostic and Management Traps

• A normal anion gap does not exclude salicylate poisoning. Some analyzers report falsely elevated chloride in the presence of salicylate. [15]

• Do not use the Done nomogram. It is unreliable for modern acute and chronic poisoning. [1,16]

• Do not withhold bicarbonate because the blood pH is already mildly alkalemic from respiratory alkalosis. [1]

• Do not assume a falling salicylate concentration means the patient is improving if pH or mental status is worsening.

• Hyperpnea is compensatory and is not itself an indication for intubation. [1]

• Do not apply an adult fixed bicarbonate infusion rate to children. Titrate to weight and physiologic targets.

• Keep dialysis initiation, chronic/delayed dialysis consideration, ECTR cessation, bicarbonate discontinuation, and discharge as separate clinical decisions; no single concentration determines all of them.

Gastrointestinal Decontamination

The 2026 Clinical Toxicology Recommendations Collaborative provides formulation-specific activated-charcoal recommendations for salicylate. Additional-dose charcoal to complete decontamination is distinct from MDAC intended to enhance elimination. [3]

Immediate-Release Salicylate, Dose at Least 200 mg/kg

If ongoing absorption is suspected, activated charcoal may still be administered beyond 6 hours for gastrointestinal decontamination. [3]

Modified-Release Salicylate, Dose at Least 200 mg/kg

Additional-Dose Charcoal

Use the same charcoal dose as the initial dose: 50 g in adults or 1 g/kg in children up to the adult dose. An additional dose may be given when ongoing absorption is suspected, including rising concentrations, very large ingestion, modified-release product, or suspected pharmacobezoar. [3]

MDAC specifically intended to enhance elimination requires individualized risk assessment. Salicylate is not on the CTRC list of poisons for which enhanced-elimination MDAC is endorsed. [3,20–22]

Do not intubate routinely just to administer charcoal. Assess airway protection, aspiration risk, and gastrointestinal function before each charcoal dose. Do not induce emesis. [3,4]

Whole-bowel irrigation is not routine. Consider it only after toxicology consultation for selected potentially toxic sustained-release or enteric-coated ingestions, particularly when delayed presentation and possible remaining gastrointestinal drug burden are present. Do not delay resuscitation, bicarbonate, or hemodialysis to perform WBI. [23]

Serum and Urine Alkalinization

IV sodium bicarbonate is the first-line specific therapy. Serum alkalinization reduces CNS penetration, while urinary alkalinization increases renal salicylate clearance. [1,27–30]

When Alkalinization Is Not Working

1. Correct hypokalemia and magnesium deficiency.

2. Correct hypovolemia.

3. Confirm that the ordered bicarbonate is actually being delivered.

4. Reassess renal function.

5. Recognize volume intolerance or pulmonary/cerebral edema as reasons to move toward dialysis rather than continuing to force bicarbonate.

Back Off When

• Blood pH rises above approximately 7.55–7.60: reduce or pause bicarbonate and reassess; this is a MedicalToxic operational safety trigger. [Expert]

• Hypernatremia develops.

• Volume overload appears.

• Alkalosis-induced hypocalcemia becomes symptomatic.

Airway and Ventilation

Hyperpnea is compensation, not a reason to intubate.

The major danger during necessary intubation is peri-intubation acidemia caused by apnea, CO₂ retention, or inadequate post-intubation minute ventilation. [1,5,6]

Intubation may be indicated for deteriorating mental status or acute lung injury with failing oxygenation or ventilation, and should be considered for significant, uncontrollable agitation. [1]

• Minimize apnea.

• Use the most experienced operator available and prioritize first-pass success. [6]

• An IV sodium bicarbonate bolus at the time of intubation sufficient to maintain blood pH 7.45–7.50 over the next 30 minutes is a reasonable management option. [1]

• In an acidemic patient with spontaneous PCO₂ <20 mmHg, use an IV bicarbonate bolus and/or bag-mask hyperventilation. [1]

• Match or exceed the pre-intubation minute ventilation after intubation.

• Preserve low PCO₂ and blood pH 7.45–7.50.

• In severe poisoning, consider arranging hemodialysis before or at intubation when clinically feasible and dialysis indications are present or anticipated. [Observational / Expert; 8]

• Avoid unnecessary sedatives, opioids, and other respiratory depressants in spontaneously breathing patients because suppression of compensatory ventilation can precipitate deterioration. [1]

Hemodialysis and Extracorporeal Treatment

EXTRIP separates recommended criteria (strength 1D) from suggested criteria (strength 2D). These are consensus recommendations based on very low-certainty evidence and should be interpreted together with the patient’s clinical condition. [2]

EXTRIP Recommended: Start Extracorporeal Treatment if Any Criterion Is Present

EXTRIP Suggested: Consider Extracorporeal Treatment if Any Criterion Is Present

Additional ACMT Clinical Reasons to Consider Hemodialysis

• Significant CNS abnormality, including altered mental status, cerebral edema, or seizure. [1]

• Acute lung injury or failing respiratory capacity. [1]

• Impaired glomerular filtration not responsive to volume repletion. [1]

• Deteriorating clinical condition despite standard therapy or delayed/inadequate urinary alkalinization. [1]

• Significant hyperthermia, exacerbating co-ingestion, refractory/profound electrolyte disturbance, refractory/profound acidemia, inability to give bicarbonate, or a rising salicylate concentration despite bicarbonate. [1]

Intermittent hemodialysis is preferred because it provides the highest clearance while correcting acid-base, fluid, and electrolyte abnormalities. [2]

When to Stop ECTR

EXTRIP cessation requires clinical improvement AND one of the following: [2]

• When concentrations are available: salicylate <19 mg/dL (1.4 mmol/L), with clinical improvement.

• When concentrations are not readily available: at least 4–6 hours of ECTR, with clinical improvement and reassessment.

After dialysis, recheck salicylate at 2–6 hours as a MedicalToxic operational interval, sooner for deterioration. [Expert] Rebound may reflect redistribution and/or continued absorption.

Chronic, Delayed, and Acute-on-Chronic Toxicity

Do not use concentration as the primary trigger.

In chronic or delayed toxicity, clinical condition governs. Significant toxicity with chronic salicylate exposure can occur at relatively low serum concentrations. [1]

A patient with chronic toxicity or delayed presentation who has significant CNS abnormality, acute lung injury, or other manifestations of toxicity warrants consideration for hemodialysis around a serum concentration of 40 mg/dL (2.9 mmol/L). This is an ACMT clinical consideration, not a universal hard threshold. [1]

In a deteriorating chronic patient, do not wait for a concentration to cross a numerical threshold. EXTRIP clinical criteria such as altered mental status, new hypoxemia requiring oxygen, or failure of standard therapy apply at any concentration. [2]

Special Populations

Pregnancy

Evidence in pregnancy is limited to case reports and perinatal pharmacology. No validated pregnancy-specific management or dialysis threshold exists. [31–35]

• Salicylate crosses the placenta, and fetal or neonatal concentrations may exceed simultaneous maternal concentrations. [32,33]

• Fetal toxicity may be disproportionate to maternal concentration, particularly late in gestation. [31]

• Neonatal elimination can be slow. [34]

• Obtain early obstetric and neonatal input and use fetal monitoring at viable gestational age. [Expert]

UKTIS advises that a pregnant patient who has overdosed on aspirin should generally be managed as a non-pregnant patient would be, with additional intervention and fetal monitoring as required. [35]

Children

• Use weight-based dosing. Never transfer an adult fixed mL/h bicarbonate rate to a child.

• Check glucose early; hypoglycemia is an important pediatric concern. [36]

• Chronic pediatric toxicity can be serious at relatively low concentrations.

• Hyperventilation may be absent and metabolic acidosis prominent; absence of respiratory alkalosis does not exclude significant poisoning. [1,36]

Older Adults

Chronic and acute-on-chronic exposure, renal impairment, diagnostic delay, and non-cardiogenic pulmonary edema are particularly important. Apply the chronic-toxicity framework early in an older adult with unexplained confusion and a compatible acid-base pattern.

Dermal and Topical Exposure

• Remove the product and wash skin thoroughly with soap and water; remove occlusive dressings. [Expert; 37]

• Obtain and repeat serum salicylate concentrations in symptomatic patients or after large-surface/occluded exposure because absorption may be delayed. [Expert; 37]

• Manage systemic toxicity using the same principles as oral poisoning.

• Gastrointestinal decontamination has no role for isolated dermal exposure without ingestion.

• A 2025 systematic review identified 44 published cases of systemic toxicity from topical salicylates across age groups. [37]

Monitoring, Disposition, and Clearance

Monitoring Cadence During Active or Evolving Toxicity

Recovery After Treatment for Systemic Toxicity

Before de-escalation or discharge, confirm:

• Clinical recovery with baseline mental status and stable respiratory, temperature, and hemodynamic findings.

• Reassuring serial concentrations with no evidence of ongoing absorption or clinically significant rebound.

• Stable acid-base status, electrolytes, kidney function, and glucose after poisoning-specific treatment has been discontinued as appropriate.

• An adequate post-treatment observation period based on formulation, severity, kidney function, and risk of delayed absorption.

• Co-ingestants and other medical problems have been addressed, with appropriate follow-up and return precautions.

Neither two concentrations below 30 mg/dL nor 12–24 hours of normal acid-base status is a universal clearance rule. The <19 mg/dL EXTRIP endpoint concerns dialysis cessation; the approximately 40 mg/dL ACMT example concerns dialysis consideration in symptomatic chronic/delayed toxicity. Neither is a discharge criterion. [1,2]

Every intentional ingestion requires psychiatric assessment before discharge, arranged in parallel with medical management.

Ineffective or Harmful Therapies